GMA306

GMA306 is an investigational **bispecific biologic antibody therapy** from Gmax Biopharm designed using the company's M-Body and Bibody technology platforms. The molecule combines an **antagonistic antibody against endothelin receptor type A** with a **transforming growth factor beta trap**, aiming to simultaneously reduce endothelin-driven vasoconstriction and inhibit TGF-beta-mediated fibrotic remodeling. It has been described for development in **pulmonary arterial hypertension** and **lung tissue fibrosis**, with preclinical data indicating vasoconstriction relief comparable to the standalone anti-ETa antibody GMA301 while adding anti-fibrotic activity.